The present invention provides a method for the treatment or prevention of schizophrenic disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

 
Web www.patentalert.com

< Gyrase inhibitors and uses thereof

< Reduction of matrix interference for MALDI mass spectrometry analysis

> Substituted amides

> Quaternary ammonium compounds
~ 00206